| abstract |
The present invention provides a novel compound or a pharmaceutically acceptable salt thereof having FGFR inhibitory activity, and a pharmaceutical composition comprising the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: Wherein n represents 0 to 2; A represents a arylene or a heteroarylene; G represents a single bond, an oxygen atom or -CH 2- ; E represents a nitrogen-containing non-aromatic heterocyclic ring; R 1 represents an alkoxy group, Alkoxyalkoxy or the like; R 2 represents a hydrogen atom, a halogen atom, a hydroxyl group, an alkyl group, a hydroxyalkyl group, a nitrogen-containing non-aromatic heterocyclic group or the like; and R 3 represents a hydrogen atom, an alkyl group , Alkoxy or the like, provided that when E represents an azetidine ring and R 2 or R 3 is present on a nitrogen atom on the azetidine ring, the R 2 or R 3 does not represent hydrogen atom. |